November 18th 2024
AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.
September 27th 2024
Michael A. Weber, MD, on aprocitentan approval: A new approach to managing hypertension
March 21st 2024Michael A. Weber, MD, an investigator in the PRECISION study, discusses the newly FDA approved drug aprocitentan (Tryvio), and its promise for helping patients with treatment-resistant hypertension.